Dermatology

This interview featured a discussion with Dr. Bhatia on the future of actinic keratosis diagnosis and treatment, as well as advances and important facts for clinicians to remember about risk.

These findings, presented at the Fall Clinical Dermatology conference, resulted from the ADjoin long-term extension study.

This interview at the Fall Clinical Dermatology conference featured a discussion with Dr. Bhatia regarding key insights from his talk ‘What You Need To Know NOW About Actinic Keratosis.’

Susan C. Taylor, MD, emphasizes the importance of understanding the unique biological differences and needs of individuals with skin of color.

This presentation at the Fall Clinical Dermatology conference in Las Vegas explored the topic of advancements in HS treatment.

In this episode of MEDcast, expert dermatologists discuss actinic keratosis, a premalignant skin condition. They are sharing their thoughts on the importance of early diagnosis and treatment and are delving into treatment options, in particular photodynamic treatments.

The approval for the IL-17A and IL-17F inhibitor is supported by data showing about 80% of patients achieved nearly clear skin within 4 doses.

This segment of Dr. Okoye’s interview featured a set of examples of HS patients’ struggles with access to medication, as well as discussion of potential solutions.

This interview with Dr. Okoye featured a discussion about her presentation at the SHSA conference, specifically regarding healthcare disparities for HS patients.

The findings from these 2 trials for bimekizumab may lead to greater treatment options for patients with HS, an often debilitating and chronic skin condition.

The new results from 3 different phase 3 studies presented at EADV on nemolizumab for those with prurigo nodularis and eczema show promise for the treatment.

This new data from the phase 2b trial on povorcitinib could lead to developments in the dermatology space for vitiligo patients.

This new data on the negative impacts of skin disease on individuals in 27 countries in Europe demonstrates the lasting impacts of stigmatization.

This new synthetic data set could work as a potential resource for training on AI as well as to help facilitate a consensus among clinicians.

Amid the escalating threat of wildfires due to climate change, the medical and public health communities face an increasing responsibility to develop robust emergency response plans to safeguard patients and healthcare infrastructure.

This interview segment with Dr. Harris-Tryon further explored some of the key points made in her upcoming talk regarding the microbiology of hidradenitis suppurativa.

During this interview, Dr. Harris-Tryon spoke about the most important points covered in her upcoming talk at the 8th Annual Symposium on Hidradenitis Suppurativa Advances.

This new data indicated that BHRA positivity could potentially be implemented as an omalizumab response predictor and showed the potential for off-label use.

This new research into detergent’s impact on human skin barrier dysfunction may lead to investigation by public health authorities in the near future due to its implications.

This new position statement by the Congress of the European Academy of Dermatology and Venereology identified several benefits to the implementation of technological innovations in dermatologic care.

This set of measures may promote a more accurate assessment of HS in patients as well as on their life outcomes, with the goal being shared decision-making in clinical practice.

This study also found a particularly high rate of such obstacles for SGM patients who also identify as being either non-Hispanic Black or Hispanic/Latino.

The new educational initiative was launched to provide useful insights from dermatologists as well as personal accounts by patients with seborrheic dermatitis with many different backgrounds.

A study of more than 500 patients with severe psoriasis provides further insight into the association between severe psoriasis and cardiovascular disease risk, demonstrating coronary microvascular dysfunction was present in 30% of this cohort.

The company shared anticipation that their BLA decision for bimekizumab to treat adults with plaque psoriasis will not come before the end of this month.